MedPath

A Phase I/IIb extension study assessing the long-term safety and efficacy of an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study.

Phase 2
Completed
Conditions
Christmas disease
10064477
10005330
Registration Number
NL-OMON54158
Lead Sponsor
CSL Behring LLC
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
6
Inclusion Criteria

1. Subjects with congenital hemophilia B who completed Study CT-AMT-060-01

2. Able to provide informed consent following receipt of verbal and written
information about the trial.

Exclusion Criteria

Enrolled subjects will have already been assessed based on the exclusion
criteria for Study CT-AMT-060-01.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The primary endpoint is to demonstrate the long-term safety (6-10 years) after<br /><br>dosing of AAV5-hFIX.<br /><br>Primary safety endpoints include the following:<br /><br>- AEs possibly or probably related to previous AAV5-hFIX administration<br /><br>- ALT/aspartate aminotransferase (AST) levels<br /><br>- Liver pathology (assessed by ultrasound)<br /><br>- Alpha-fetoprotein (AFP)</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>The secondary endpoints will focus on the long-term efficacy (6-10 years) after<br /><br>dosing of AAV5-hFIX on FIX activity, overall FIX utilization, bleeding events,<br /><br>any procedures and Quality of Life.<br /><br>Secondary efficacy endpoints include the following:<br /><br>- Endogenous FIX activity<br /><br>- Utilization of FIX-replacement therapy<br /><br>- Annualized bleeding rate; including the following:<br /><br>o All bleeds (treated and untreated)<br /><br>o Spontaneous bleeds<br /><br>o Traumatic bleeds<br /><br>o Joint bleeds<br /><br>- Procedures (including major and minor surgeries)<br /><br>- Short form (SF-36) and EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) QoL scores<br /><br>- Hemophilia Joint Health Score (HJHS)</p><br>
© Copyright 2025. All Rights Reserved by MedPath